Applied Genetic Technologies (AGTC) Stock Price
Applied Genetic Technologies Price
Revenue at Applied Genetic Technologies has contracted by 11.3% per year over the past 10 years to 325,000.00 USD. For Applied Genetic Technologies, the net margin of -21,213.2% is down versus -88.1% a few years ago.
Applied Genetic Technologies stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Applied Genetic Technologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Applied Genetic Technologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Applied Genetic Technologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Applied Genetic Technologies Price |
|---|
Applied Genetic Technologies Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Applied Genetic Technologies Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 0.05 | 0.04 | 0.02 | 0.04 | – | – | – | – | – | 0.01 | 0.63 | 18.09 |
| – | – | – | 100.00 | 2,250.00 | -17.02 | -38.46 | 70.83 | -95.12 | – | – | – | – | – | 5,636.36 | 2,766.88 |
| 200.00 | – | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | – | – | – | – | 100.00 | 100.00 | 100.00 |
| – | – | – | – | 0.05 | 0.04 | 0.02 | 0.04 | – | – | – | – | – | 0.01 | 0.63 | 18.09 |
| -2.00 | -3.00 | -12.00 | -24.00 | -2.00 | 1.00 | -22.00 | -4.00 | -46.00 | -58.00 | -66.00 | -75.00 | -80.00 | -81.00 | -65.00 | – |
| -200.00 | – | -1,200.00 | -1,200.00 | -4.26 | 2.56 | -91.67 | -9.76 | -2,300.00 | – | – | – | – | -736.36 | -10.30 | – |
| -1.00 | -4.00 | -15.00 | -24.00 | -1.00 | – | -21.00 | -2.00 | -45.00 | -57.00 | -68.00 | -39.00 | -66.00 | -46.00 | -41.00 | -37.00 |
| – | 300.00 | 275.00 | 60.00 | -95.83 | – | – | -90.48 | 2,150.00 | 26.67 | 19.30 | -42.65 | 69.23 | -30.30 | -10.87 | -9.76 |
| 45.00 | 45.00 | 4.00 | 16.00 | 18.00 | 18.00 | 18.00 | 18.00 | 21.00 | 33.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Applied Genetic Technologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Applied Genetic Technologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Applied Genetic Technologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Applied Genetic Technologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Applied Genetic Technologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Applied Genetic Technologies stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Applied Genetic Technologies Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Applied Genetic Technologies business model & stock analysis
Applied Genetic Technologies SWOT Analysis
Strengths
Applied Genetic Technologies Corp (AGTC) has developed strong in-house expertise in gene therapy, allowing them to develop innovative solutions for genetic diseases.
They have a robust intellectual property portfolio, giving them a competitive advantage and protecting their innovations from imitation.
AGTC has established strategic collaborations with leading research institutions and pharmaceutical companies, enabling access to resources, expertise, and potential market opportunities.
Weaknesses
AGTC's current product portfolio is limited, with a focus on ophthalmology-related gene therapies. This narrow product range exposes them to market risks and limits their revenue potential.
The long development timelines associated with gene therapy pose a challenge, potentially delaying the commercialization of AGTC's products and increasing costs.
AGTC heavily relies on external sources for funding, which may result in financial instability and dependence on investors' decisions.
Opportunities
The gene therapy market is expected to grow significantly in the coming years, presenting AGTC with opportunities to expand their product portfolio and capture a larger market share.
Advancements in gene editing technologies offer potential for AGTC to enhance their gene therapies and develop novel treatments for previously untreatable genetic diseases.
AGTC's partnerships and collaborations can lead to valuable research outcomes and potential licensing or commercialization agreements, increasing their revenue streams.
Threats
Increased competition in the gene therapy sector poses a threat to AGTC's market position and pricing power. Other companies with similar technologies or novel approaches could overshadow their offerings.
Regulatory uncertainties and evolving ethical concerns surrounding gene therapies can impact AGTC's ability to gain necessary approvals and cause delays in product development and commercialization.
Negative public sentiment or skepticism towards gene therapy, driven by safety concerns or lack of awareness, may hinder market acceptance of AGTC's products.
Applied Genetic Technologies Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Applied Genetic Technologies Segments
Applied Genetic Technologies Revenue by Segment (1/3)
3 Years
5 Years
Max
Details
Applied Genetic Technologies Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
Applied Genetic Technologies Revenue by Segment (3/3)
3 Years
5 Years
Max
Details
Applied Genetic Technologies Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Applied Genetic Technologies historical P/E ratio, EBIT multiple, and P/S ratio
Applied Genetic Technologies annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Applied Genetic Technologies shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Applied Genetic Technologies Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 10/25/2022 | Maintained | Equal Weight | 55 | |
| 10/25/2022 | Downgrade | BuyNeutral | – | |
| 10/24/2022 | Downgrade | OutperformNeutral | 58 | |
| 10/24/2022 | Downgrade | BuyHold | 56 | |
| 10/4/2022 | Downgrade | OverweightEqual Weight | 55 | |
| 9/30/2022 | Maintained | Buy | 56 | |
| 9/30/2022 | Maintained | Buy | – | |
| 9/29/2022 | Downgrade | BuyNeutral | 52 | |
| 9/28/2022 | Maintained | Buy | – | |
| 5/18/2022 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Applied Genetic Technologies Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/15/2023 | -0.19USD | - | 0.00USD | - | 2023 Q3 |
| 2/13/2023 | -0.30USD | - | 0.00USD | - | 2023 Q2 |
| 11/29/2022 | -0.29USD | - | 0.00USD | - | 2023 Q1 |
| 9/27/2022 | -0.34USD | - | 0.00USD | - | 2022 Q4 |
| 5/16/2022 | -0.44USD | - | 0.00USD | - | 2022 Q3 |
| 2/14/2022 | -0.39USD | - | 0.00USD | - | 2022 Q2 |
| 11/9/2021 | -0.36USD | - | 84,579.00USD | - | 2022 Q1 |
| 9/23/2021 | -0.41USD | - | 0.00USD | - | 2021 Q4 |
| 5/17/2021 | -0.42USD | - | 0.00USD | - | 2021 Q3 |
| 2/11/2021 | -0.60USD | - | 0.00USD | - | 2021 Q2 |
Applied Genetic Technologies shareholder structure
| % | Name |
|---|---|
4.40045% | |
3.56554% | |
3.32909% | |
3.11900% | |
2.70050% | |
2.03375% |
Applied Genetic Technologies Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
9.90% | SEC ↗ | |
9.80% | SEC ↗ | |
8.70% | SEC ↗ |
Applied Genetic Technologies Executives and Management Board
15 members · avg. age 61 · 40 % women
Ms. Susan Washer (60)
President, Chief Executive Officer, Director · since 2002
1.44 M USD
Management
Mr. Stephen Potter (65)
Chief Business Officer
Mr. Jonathan Lieber (53)
Chief Financial Officer
Mr. Abraham Scaria
Chief Science Officer
Ms. Sarah Disalvatore
Vice President - Clinical Operations
Ms. Hope D'oyley-gay
General Counsel
Dr. Susan Schneider (63)
Chief Medical Officer
Board of Directors
Dr. Scott Koenig (69)
Independent Chairman of the Board
Dr. Ivana Magovcevic-Liebisch (54)
Independent Director
Ms. Anne Vanlent (74)
Independent Director
Mr. Edward Hurwitz (58)
Independent Director
Mr. William Aliski (74)
Independent Director
Mr. James Rosen (52)
Independent Director
Frequently asked questions about Applied Genetic Technologies
The business model of Applied Genetic Technologies Corp (AGTC) focuses on developing and commercializing gene therapies to treat rare genetic diseases. AGTC utilizes its expertise in gene therapy and adeno-associated virus (AAV) vectors to develop treatments for eye diseases, such as X-linked retinoschisis (XLRS) and achromatopsia. By utilizing its proprietary gene delivery platform, AGTC aims to address unmet medical needs and provide potential therapies for patients suffering from inherited disorders. With a commitment to advancing gene therapies, AGTC strives to improve the quality of life for individuals affected by rare genetic diseases.
Applied Genetic Technologies Corp (AGTC) primarily operates in the biotechnology industry. Their expertise lies in developing gene therapy products for the treatment of various inherited eye diseases. AGTC focuses on developing innovative solutions that target rare diseases caused by genetic mutations. By leveraging their expertise in adeno-associated virus (AAV) gene therapy, AGTC aims to provide transformative treatments in the ophthalmology field. With their commitment to advancing genetic medicine, Applied Genetic Technologies Corp is dedicated to improving the quality of life for patients suffering from inherited eye diseases.
The main competitors of Applied Genetic Technologies Corp in the market include companies such as Biogen Inc., Spark Therapeutics Inc., and Regenxbio Inc.
Applied Genetic Technologies Corp (AGTC) is a leading biotechnology company specializing in the development of gene therapies for rare diseases. Established in 1999, AGTC has a strong history and background in the field of genetic medicine. The company's mission is to develop and commercialize innovative therapies that can potentially transform the lives of patients. AGTC utilizes its expertise in gene therapy and vector development to target various genetic disorders affecting the eyes, central nervous system, and the muscular system. With a commitment to advancing gene-based treatments, AGTC has emerged as a prominent player in the biotechnology industry.
Applied Genetic Technologies Corp (AGTC) has achieved several significant milestones. One of the noteworthy achievements was the successful completion of a Phase I/II clinical trial for its lead product candidate, treating X-linked retinitis pigmentosa. The company also received orphan drug designation from the FDA for this candidate. Furthermore, AGTC secured a collaboration agreement with Biogen to develop gene-based therapies for multiple ophthalmic diseases. Additionally, the company successfully raised funds through public offerings and private placements to support its research and development efforts. These achievements highlight AGTC's dedication to advancing gene therapy treatments and its commitment to making a positive impact in the field.
Applied Genetic Technologies Corp (AGTC) is primarily present in the United States. As a leading biotechnology company, AGTC focuses on developing and commercializing innovative gene therapies for patients with rare eye diseases. With its headquarters based in Florida, AGTC operates primarily in the US market. The company collaborates with renowned medical centers and academic institutions across the country to advance its research and clinical trials. AGTC's presence and expertise in the United States contribute to its mission of providing life-changing treatments for patients in need.
Applied Genetic Technologies Corp (AGTC) is committed to pursuing innovation and excellence in the field of genetic therapies. As a leading biotechnology company, AGTC focuses on developing gene-based treatments for rare inherited diseases, working with precision and compassion. The company's core values include collaboration, integrity, and patient-centricity. AGTC's corporate philosophy revolves around leveraging cutting-edge technology and scientific knowledge to bring novel therapies to patients in need. With a dedicated research and development team, and strategic partnerships, AGTC strives to improve the lives of individuals affected by rare genetic disorders through its groundbreaking treatments.
10 analysts currently rate the Applied Genetic Technologies stock: 0 recommend buying, 7 holding and 3 selling.
The Applied Genetic Technologies share (AGTC) is listed on 3 stock exchanges, including: NASDAQ (AGTC), Frankfurt (2GT.F), München (2GT.MU).
Applied Genetic Technologies Corporation (AGTC) is a leading biotechnology company specializing in the development of gene therapies for rare eye diseases. The company was founded in 1999 and is headquartered in Gainesville, Florida. AGTC's business model is based on the research and development of gene therapies for rare eye diseases, particularly diseases of the retina that can lead to blindness. AGTC focuses on a platform technology based on adeno-associated virus (AAV) vector technology. The company has two main products currently in the clinical development phase: the XLRS program and the RP program. The XLRS program is a gene therapy for the treatment of X-linked retinoschisis (XLRS). The RP therapy is a gene therapy for the treatment of retinitis pigmentosa (RP). AGTC pursues a differentiated strategy in the field of gene therapy by focusing on rare eye diseases and prioritizing the development of therapies with high efficacy and safety. The company has a strong collaboration strategy aimed at accelerating both scientific and business development. The company has partnerships with leading academic institutions and companies to accelerate research and development of gene therapy programs. AGTC has also formed a strategic alliance with Biogen, a leading biopharmaceutical company that has brought a wide range of innovative therapies to market. The alliance includes joint development of gene therapies for rare eye diseases, as well as joint exploration and development of gene therapeutics. Like most biotechnology companies, AGTC relies on a pipeline-based strategy. The company has a broad range of gene therapy programs in the development phase and prioritizes them to accelerate the most needed treatment options. Overall, AGTC's business model is focused on developing and commercializing gene therapies for rare eye diseases, based on a platform technology that utilizes adeno-associated virus (AAV) vector technology. The company has a differentiated strategy and strong partnerships to accelerate the development of gene therapies and provide high efficacy and safety to the patient population.
The revenue cannot currently be calculated for Applied Genetic Technologies.
The profit cannot currently be calculated for Applied Genetic Technologies.
The P/E ratio cannot be calculated for Applied Genetic Technologies at the moment.
The P/S cannot be calculated for Applied Genetic Technologies currently.
The Eulerpool Quality Score for Applied Genetic Technologies is 1/10.
The ISIN of Applied Genetic Technologies is US03820J1007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Applied Genetic Technologies is A110V2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Applied Genetic Technologies is AGTC. The ticker symbol is used to trade Applied Genetic Technologies shares on the stock exchange.
Applied Genetic Technologies is assigned to the 'Health' sector.
The dividends of Applied Genetic Technologies are distributed in USD.
Applied Genetic Technologies stock
Applied Genetic Technologies Peer Group
Applied Genetic Technologies Ticker
Applied Genetic Technologies FIGI
All fundamentals and in-depth analysis of Applied Genetic Technologies
Our stock analysis for Applied Genetic Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Applied Genetic Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.